Pharmacological maintenance treatments of opiate addiction
- PMID: 23210630
- PMCID: PMC4014029
- DOI: 10.1111/bcp.12051
Pharmacological maintenance treatments of opiate addiction
Abstract
For people seeking treatment, the course of heroin addiction tends to be chronic and relapsing, and longer duration of treatment is associated with better outcomes. Heroin addiction is strongly associated with deviant behaviour and crime, and the objectives in treating heroin addiction have been a blend of humane support, rehabilitation, public health intervention and crime control. Reduction in street heroin use is the foundation on which all these outcomes are based. The pharmacological basis of maintenance treatment of dependent individuals is to minimize withdrawal symptoms and attenuate the reinforcing effects of street heroin, leading to reduction or cessation of street heroin use. Opioid maintenance treatment can be moderately effective in suppressing heroin use, although deviations from evidence-based approaches, particularly the use of suboptimal doses, have meant that treatment as delivered in practice may have resulted in poorer outcomes than predicted by research. Methadone treatment has been 'programmatic', with a one-size-fits-all approach that in part reflects the perceived need to impose discipline on deviant individuals. However, differences in pharmacokinetics and in side-effects mean that many patients do not respond optimally to methadone. Injectable diamorphine (heroin) provides a more reinforcing medication for some 'nonresponders' and can be a valuable option in the rehabilitation of demoralized, socially excluded individuals. Buprenorphine, a partial agonist, is a less reinforcing medication with different side-effects and less risk of overdose. Not only is it a different medication, but also it can be used in a different paradigm of treatment, office-based opioid treatment, with less structure and offering greater patient autonomy.
Keywords: addiction; buprenorphine; diamorphine; heroin; methadone.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Similar articles
-
Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?Br J Clin Pharmacol. 2014 Feb;77(2):272-84. doi: 10.1111/bcp.12031. Br J Clin Pharmacol. 2014. PMID: 23145768 Free PMC article. Review.
-
Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.Eur J Clin Pharmacol. 2011 Oct;67(10):1053-9. doi: 10.1007/s00228-011-1049-9. Epub 2011 May 3. Eur J Clin Pharmacol. 2011. PMID: 21538146 Clinical Trial.
-
Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT).Addiction. 2015 Mar;110(3):479-90. doi: 10.1111/add.12748. Epub 2014 Nov 7. Addiction. 2015. PMID: 25251885 Clinical Trial.
-
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.J Subst Abuse Treat. 2013 Jan;44(1):97-102. doi: 10.1016/j.jsat.2012.04.003. Epub 2012 Jun 15. J Subst Abuse Treat. 2013. PMID: 22703715 Clinical Trial.
-
Supervised Injectable Heroin: A Clinical Perspective.Can J Psychiatry. 2017 Jul;62(7):451-456. doi: 10.1177/0706743716673966. Epub 2016 Oct 6. Can J Psychiatry. 2017. PMID: 28683227 Free PMC article. Review.
Cited by
-
Frontal Lobe Functions, Demoralization, Depression and Craving as Prognostic Factors and Positive Outcomes of Patients with Heroin Use Disorder Receiving 6 Months of Methadone Maintenance Treatment.Int J Environ Res Public Health. 2022 Mar 20;19(6):3703. doi: 10.3390/ijerph19063703. Int J Environ Res Public Health. 2022. PMID: 35329387 Free PMC article.
-
Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy.J Clin Med. 2019 Jul 25;8(8):1105. doi: 10.3390/jcm8081105. J Clin Med. 2019. PMID: 31349687 Free PMC article.
-
Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.J Addict Med. 2019 Sep/Oct;13(5):354-361. doi: 10.1097/ADM.0000000000000505. J Addict Med. 2019. PMID: 30747750 Free PMC article.
-
Methadone in the madness: a case series and review of methadone management in hospital settings.Pain Manag. 2025 Apr;15(4):191-198. doi: 10.1080/17581869.2025.2479411. Epub 2025 Mar 31. Pain Manag. 2025. PMID: 40162830 Free PMC article. Review.
-
A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888. eCollection 2019. Front Psychiatry. 2019. PMID: 31866884 Free PMC article.
References
-
- UNODC 2007. United Nations Office on Drugs and Crime. New York: United Nation; 2007. World Drug Report.
-
- Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–229. - PubMed
-
- Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002;97:1383–1394. - PubMed
-
- Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas 1994–2002. Drug Alcohol Depend. 2005;78:73–81. - PubMed
-
- Passini S. The delinquency-drug relationship: the influence of social reputation and moral disengagement. Addict Behav. 2012;37:577–579. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical